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research paper
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Summary
Systemic mastocytosis (SM) is a rare myeloproliferative disease without
curative therapy. Despite clinical variability, the majority of patients harbour a KIT-D816V mutation, but efforts to inhibit mutant KIT with tyrosine kinase inhibitors have been unsatisfactory, indicating a need for new
preclinical approaches to identify alternative targets and novel therapies in
this disease. Murine models to date have been limited and do not fully
recapitulate the most aggressive forms of SM. We describe the generation
of a transgenic zebrafish model expressing the human KIT-D816V mutation. Adult fish demonstrate a myeloproliferative disease phenotype, including features of aggressive SM in haematopoeitic tissues and high expression
levels of endopeptidases, consistent with SM patients. Transgenic embryos
demonstrate a cell-cycle phenotype with corresponding expression changes
in genes associated with DNA maintenance and repair, such as reduced
dnmt1. In addition, epcam was consistently downregulated in both transgenic adults and embryos. Decreased embryonic epcam expression was
associated with reduced neuromast numbers, providing a robust in vivo
phenotypic readout for chemical screening in KIT-D816V-induced disease.
This study represents the first zebrafish model of a mast cell disease with
an aggressive adult phenotype and embryonic markers that could be
exploited to screen for novel agents in SM.
Keywords: zebrafish, systemic mastocytosis, transgenesis, KIT D816V,
receptor tyrosine kinase.
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Mast cells are well known to play critical roles in both innate
and adaptive immune responses, as well as allergic reactions
and inflammation (Theoharides & Kalogeromitros, 2006;
Metcalfe, 2008). Similarly, mast cells have been implicated in
autoimmune conditions (Metcalfe, 2008) and neoplastic processes (Ribatti et al, 2004, 2009). The elucidation of the various functions of mast cells has been largely due to the
characterization of their receptors, KIT and FCeRI, and their
respective signal transduction pathways responsible for
growth, differentiation, survival and physiological functions
(Metcalfe, 2008). Perturbed mast cell development and proliferation results in a pathological accumulation of mast cells,
known as mastocytosis and classified among the myeloproliferative disorders (Robyn & Metcalfe, 2006; Takemoto et al,
First published online 2 July 2014
doi: 10.1111/bjh.12999

2009). The clinical spectrum of systemic mastocytosis (SM)
encompasses a wide range of clinical presentations, from a
localized skin disease to an aggressive leukaemia (Metcalfe &
Akin, 2001; Patnaik et al, 2007; Pardanani, 2012). Most
patients harbour a common point mutation in the KIT gene,
namely the Asp816Val (D816V) substitution. KIT is a transmembrane receptor with intrinsic tyrosine kinase activity
found on many types of haematopoietic cells, however, only
mast cells retain high levels of KIT expression in their mature
form, while others gradually lose KIT expression after
the progenitor stage (Metcalfe, 2008). This mutation leads
to pathological constitutive phosphorylation of the KIT
receptor, resulting in activation of downstream effectors,
such as Ras/Raf/MAPK and JAK/STAT pathways, that lead to
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increased mast cell migration and survival and contribute to
disease pathogenesis (Nagata et al, 1995; Longley et al, 1996;
Metcalfe & Akin, 2001; Pardanani, 2012). Despite this specific defect leading to activation of a protein kinase receptor,
to date there is no effective targeted therapy available for
SM. Moreover, the same KIT-D816V mutation is present
across the spectrum of SM phenotypes, indicating that additional genetic lesions and/or activation of parallel pathways
collaborate to induce a more aggressive disease. Current
treatment is tailored to patient symptoms and management
in advanced disease is not standardized (Metcalfe, 2008;
Pardanani, 2012). Pertinent animal models of SM are necessary preclinical tools to elucidate contributing molecular
pathways in disease pathogenesis and as a platform for in
vivo screening of novel therapeutics.
Mouse models of SM created by employing different
approaches have been published. Zappulla et al (2005) used
the primate chymase promoter to drive the human KITD816V mutation and observed a spontaneous accumulation
of mast cells in tissues and at least one mast cell tumour in
30% of adult transgenic animals. More recently, Gerbaulet
et al (2011) described mast cell hyperplasia, B-lymphocyte
neoplasia and colitis in their inducible Cre/loxP-based transgenic mouse model, where they overexpressed the murine
homolog of the human KIT-D816V mutation, Kit-D814V.
While providing valuable insight into the transforming capabilities of KIT and mastocytosis-like findings, this model was
associated with a 75% perinatal lethality of transgenic animals. The phenotypes observed revealed the pleiotropic
effects of mutant KIT, but limited the possibility of studying
the effects of the mutation into adulthood.
In the last two decades, the zebrafish (Danio rerio) has
emerged as a powerful tool for modelling human diseases,
due to its many advantages as an experimental vertebrate.
Highly conserved genetics together with advancements in
transgenic technology and traceable development in externally developing transparent embryos have enabled the successful establishment of an increasing number of human
disease models (Langenau et al, 2003; Patton et al, 2005;
Santoriello et al, 2010; Chen & Langenau, 2011). Furthermore, the ease and availability of genetic manipulation and
unprecedented live imaging capabilities have provided valuable insight into vertebrate haematopoietic and immunological development and cell function (Berman et al, 2003;
Traver et al, 2003; Martin & Feng, 2009; Jing & Zon, 2011;
Yoo et al, 2011; Renshaw & Trede, 2012).The zebrafish also
has an inherent capacity to accommodate high-throughput
chemical modifier screens, which have previously identified
effective compounds in a variety of disease states in zebrafish
models (Peterson et al, 2000; Burns et al, 2005; North et al,
2007; Yeh et al, 2009; Tsang, 2010). We employed these
opportunities to identify mast cells and a specific lineage
marker (carboxypeptidase A5) in the zebrafish (Dobson et al,
2008); demonstrate structural and functional conservation of
these cells (Da’as et al, 2011) and, more recently, elucidate
ª 2014 John Wiley & Sons Ltd
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the role of Notch signalling in the transcriptional regulation
of mast cell lineage commitment (Da’as et al, 2012). Given
this conservation of mast cell biological processes, we wanted
to exploit the advantages of the zebrafish system to study hyperproliferative mast cell diseases. Here we describe a transgenic zebrafish model of SM generated using the human
KIT-D816V mutation that exhibits a mast cell proliferative
phenotype in adult fish and results in changes in specific
embryonic markers, providing a new in vivo tool for future
experiments and drug screening in this disease model. The
overall importance of the zebrafish model of SM lies in additional experimental opportunities for studies of this disease
that may not be available in other model systems.

Methods
Zebrafish husbandry and maintenance
Zebrafish husbandry was carried out according to standard
protocols (Westerfield, 2007). The use of zebrafish in these
studies has been approved by the Dalhousie University
Committee on Laboratory Animals, under protocol number
11–128. Embryos lacking pigmentation were obtained
through incubation in embryo media containing 0003%
N-phenylthiourea (P7629; Sigma-Aldrich, St. Louis, MO,
USA). Embryos were dechorionated by incubating them for
10 min in 1 ml of egg water after adding 100 ll of 10 mg/
ml stock solution of Pronase (10165921001; Roche Applied
Science, Laval, QC, Canada).

Generation of transgenic zebrafish lines and screening for
transgene insertion by polymerase chain reaction and
sequence analysis
For cloning the actb2::KIT-D816V::2AeGFP construct we used
the previously available p5E-actb2 vector and pDestTol2pA2
destination vector (Tol2kit). p3E-T2A-EGFP was obtained
from the laboratory of Dr Nathan Lawson (University of
Massachusetts Medical School, Worcester, MA, USA). The
KIT-D816V plasmid was kindly provided by Dr Gary Gilliland, (Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA) and was used
for making the middle-entry vector containing KIT-D816V
without a stop codon, generated from a polymerase
chain reaction (PCR) product amplified using primers CKITattB1f: 50 ggggacaagtttgtacaaaaaagcaggctcaatgagaggcgctcgcggc30
and CKITattB2r: 50 ggggaccactttgtacaagaaagctgggtagacatcgtcg
tgcacaag30 and recombined with the pDONR221. The entry
clone and whole vector recombination checking were performed as described before (Kwan et al, 2007). The actb2::
KIT-D816V::2AeGFP construct was injected into zebrafish
eggs at a concentration of 100 ng/ll, along with Tol2 transposase mRNA, also at 100 ng/ll (Fig 1A). Injected embryos
were raised to adulthood (F0) and crossed to wild-type (AB
strain) fish. Founder fish were identified by screening the F1
49
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Fig 1. Transgenic zebrafish express human KIT-D816V ubiquitously under the control of the zebrafish beta-actin promoter. (A) Schematic representation of the Tg(bactin::KIT-D816V::2AeGFP) construct generated using the MultiSite Gateway Technology. The human KIT gene with the
D816V mutation was cloned between the ubiquitous zebrafish beta-actin promoter and green fluorescent protein (GFP) along with the viral cotranslational cleavage peptide 2A. The final construct was flanked by Tol2 sites to facilitate transposase-mediated genomic integration. (B)
Embryos were screened according to ubiquitous enhanced GFP (eGFP) expression. A 72 hpf KIT-D816V F4C transgenic embryo is shown (scale
bar is 05 mm). (C) Ubiquitous eGFP expression was maintained into adulthood. A 12-month-old KIT-D816V F3C transgenic fish is shown (the
scale bar is 05 cm). (D) PCR of genomic DNA extracted from KIT-D816V transgenic and wild type fish confirm the presence of the human KIT
gene in the transgenic fish. (E) Sequencing traces of the PCR products from (D) displaying the g.2468A>T substitution corresponding to the
p.D816V mutation, shown in red. (F) Anti-KIT Western blotting of 3 dpf wild-type and KIT-D816V transgenic larval lysates as well as of a positive control lysate from the HMC-1 human cell line known to express KIT-D816V (dpf = days post-fertilization). WB, Western blot.

offspring for ubiquitous green fluorescent protien (GFP)
expression under a Leica MZ16F fluorescent microscope.
Subsequent generations were maintained by crossing strongly
positive transgenic fish. The ubiquitous GFP expression was
observed into adulthood in about 70% of the fish.
The presence of the human KIT-D816V gene in transgenic
zebrafish was confirmed by PCR and subsequent sequence
analysis. A small part of the tail of an adult fish was clipped
under anesthesia and sterile conditions. DNA was isolated
from the fin clips using the REDExtract-N-Amp Tissue PCR
Kit (XNATR-1KT; Sigma-Aldrich) according to the manufacturer’s instructions. PCR was carried out using the following
primers: KIT2255F: 50 aaagagatgtgactcccgcc30 , KIT2942R:
50 gacatcgtcgtgcacaagcag30 . Products of 683 bp were visualized
on a 1% agarose gel and extracted from the gel for sequencing. The trace images were produced using the free Sequence
Scanner software (Applied Biosystems, Foster City, CA, USA)
of the 2468A>T substitution representing the D816V mutation.

Western blotting
Zebrafish embryos were deyolked as described previously
(Westerfield, 2007) and lysed in the lysis buffer [10 mmol/l
50

Tris-HCl, pH 74, and 1% sodium dodecyl sulfate (SDS)]
containing Complete Protease Inhibitor Cocktail (116974
98001; Roche Applied Science) and 1 mmol/l phenylmethanesulfonyl fluoride (PMSF) using 1-ml syringes with
22G needles. Proteins were resolved by SDS-polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred to a nitrocellulose membrane. Non-specific sites were blocked with 5%
milk in Tris-buffered saline with Tween (TBST) before incubation with primary antibodies. We used anti-KIT antibodies
(sc-365504; Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and anti-beta-actin antibodies (4967; Cell Signaling Technology, Danvers, MA, USA). Signals were detected SuperSignal
West Pico substrate (34077; Fisher Scientific, Ottawa, ON,
Canada) and exposure to X-ray film.

Whole mount in situ hybridization assays
Digoxigenin- and fluorescein-labelled RNA probes for zebrafish cpa5, mpx, spi1b, csf1a, lcp1, gata1, hbbe3, gata2, cebpa,
were transcribed from linearized plasmids containing corresponding cDNAs according to manufacturer’s protocol
(11175025910; Roche Molecular Biochemicals, Indianapolis,
IN, USA). Probes for rrm2b, chtf18, rad23b, dnmt1, mt2 and
epcam were transcribed from the PCR products containing a
ª 2014 John Wiley & Sons Ltd
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T7 promoter (for sequences see Table SI). Whole mount
in situ hybridization (WISH) assays were performed on
embryos fixed in 4% paraformaldehyde at different timepoints as described previously (Dobson et al, 2008). Images
were taken on a Leica MZ16F microscope with a Leica DFC
490 camera (59 objective; Leica, Wetzlar, Germany). Micrographs are representative of at least two independent trials
with 15–20 embryos per genotype.

Whole mount immunofluorescence assays for apoptosis
and cell cycle
Fixed and permeabilized embryos were used to perform
immunofluorescence (IF) for phosphorylated histone-H3
(pH3) as described in the literature with modifications
(Shepard et al, 2004) or activated Caspase-3 (casp3) as per
Jette et al (2008). The primary antibodies used were rabbit
anti-p-Histone H3 (Ser10)-R IgG(sc-8656-R; Santa Cruz Biotechnology) and rabbit anti-Caspase-3, Active Form, (clone
C92-605) IgG (559565; BD Pharmingen, Mississauga, ON,
Canada). Secondary antibodies used were Alexa Fluor 565
goat anti-rabbit/-mouse IgG (A-11011 and A11004; Life
Technologies, Carlsbad, CA, USA). Z-stack projections for IF
were captured on a Zeiss AxioObserver.Z1 microscope (59
and 109 objectives) with a Zeiss AxioCamHRm camera
running ZEISS AXIOVISION, Release 4.8 software (Carl Zeiss
Microimaging GmbH, Goettingen, Germany). Fluorescence
micrographs were processed using MACBIOPHOTONICS IMAGEJ,
Version 1.43 m (Sidi et al, 2008). Micrographs are representative of at least two independent trials with 15–20 embryos
per genotype. Fluorescence images were quantified by applying the same threshold to all images to select only the most
highly labelled cells and the labelled area was measured. Data
are reported as mean values  standard error of the mean
(SEM). Statistical analysis was performed using two-tailed
student’s t-test.

Immunohistochemistry– tryptase staining protocol
Slides were deparaffinized and antigen retrieval was performed using 001 mol/l Na-Citrate Buffer, pH: 61 in a decloaking chamber (Biocare Medical, Concord, CA, USA).
Endogenous peroxidase activity was quenched in 3% H2O2
in phosphate-buffered saline (PBS) for 10 min. Slides were
then incubated with normal horse serum diluted 1:20 in PBS
for 1 h at room temperature in a humid chamber. Tryptase
primary antibody (M7052; Dako Canada, Burlington, ON,
Canada) was diluted at 1:400 in PBS and applied to slides
overnight in a humid chamber. Slides were washed three
times in PBS between immunostaining steps and LSAB+ System-HRP Kit (K0689; Dako Canada) was applied according
to manufacturer’s directions. The reaction was visualized by
using a liquid 3,30 -diaminobenzidine (DAB) + Substrate
Chromogenic System (K3467; Dako Canada) and counterstained with Mayer’s Haematoxylin. Slides were dehydrated
through graded alcohols, xylene and mounted with Cytoseal
TM60 for microscopic evaluation. Appropriate isotype negative and positive controls were performed to validate immunostain.

Adult zebrafish kidney dissections
Zebrafish adult kidneys were dissected according to Gerlach
et al (2011). For microarray experiments, kidneys from three
wild-type and from three diseased KIT-D816V adult zebrafish
were dissected for RNA extraction. The age of wild-type
adults was 18 months and that of KIT-D816V adult fish was
approximately 24 months. The discrepancy between the ages
of the two groups was due to availability constraints of aged
wild-type strains at the time of the experiment. Kidney tissue
was pooled for each group and used directly to extract RNA
as below.

RNA isolation and microarray
Sectioning, histochemical stains and imaging
Adult fish were fixed in 10% neutral buffered formalin. Standard protocols were used for staining 5-lm sections for haematoxylin and eosin (H&E), Periodic Acid Schiff (PAS) and
stains. Cytological and histopathological analysis of zebrafish
sections was performed on-site at the IWK Health Centre.
Tissue sections were visualized using an Olympus BX51
microscope (29, 409, and 1009 objectives) with an Olympus DP25 colour camera (Olympus America Inc., Center
Valley, PA, USA) and a Zeiss AxioObserver.Z1 microscope
(59 and 109 objectives) with a Zeiss AxioCamHRm camera
running ZEISS AXIOVISION, Release 4.8 software (Carl Zeiss Microimaging GmbH). Age of onset and prevalence of disease
between different founder lines was analysed using a student’s t-test and Fisher’s exact test respectively with a P value
<005 considered significant.
ª 2014 John Wiley & Sons Ltd
British Journal of Haematology, 2014, 167, 48–61

RNA was extracted using a combination of the TRIzol
(15596-026; Life Technologies) protocol and the RNeasy
Mini Kit (74104; QIAGEN, Toronto, ON, Canada). Briefly,
embryos or dissected kidneys were homogenized in TRIzol
and centrifuged after treatment with chloroform to reveal the
three-layered product. The supernatant containing RNA was
precipitated in an equal volume of 70% ethanol and transferred into the spin columns of the RNeasy kit and purified
according to manufacturer’s instructions. Prior to use in
labelling, RNA quality was assessed using the Experion bioanalyzer capillary electrophoresis system and total RNA standard sense chips (700-7153; Bio-Rad, Mississauga, ON,
Canada) according to manufacturer’s instructions. All RNA
samples used in these experiments had RNA quality indices
(RQI) of 8 or higher (out of 10) with corresponding low levels of degradation. Subsequently, 1 lg of each RNA sample
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to be analysed was amplified using the Ambion Amino-AllylMessageAmp II aRNA amplification kit (AM1753; Life Technologies) according to the manufacturer’s instructions. The
quantity of amplified aRNA was assessed using the NanoDrop 2000 spectrophotometer (Nano-Drop; Thermo Scientific, Wilmington, DE, USA) and the quality and size
distribution, were assessed by Experionbioanalyzer (Bio-Rad).
The aRNA samples were then covalently labelled with AlexaFluor 555 or AlexaFluor 647 dyes as per kit instructions
(A32756 and A32757; Life Technologies). Target aRNA yield
and labelling efficiency were assessed by NanoDrop.
Two samples were used per hybridization mixture and
were equalized for quantity (2 lg per sample) of labelled
aRNA target added. Differences in labelling efficiencies of the
two dyes were controlled through the use of dye swaps.
Labelled target mixtures were fragmented for 30 min at 60°C
using 259 fragmentation buffer – a component of the Agilent
Gene Expression Hybridization kit (5188-5242; Agilent Technologies, Santa Clara, CA, USA). Following fragmentation,
samples were made up to 60 ll with 29 GExHyb buffer (also
a component of Agilent Gene Expression Hybridization kit).
Samples were hybridized to Agilent 4x44k zebrafish V3 slides
(design ID 026437, part number G2519F) using quad chambers on the TECAN HS4800 Pro instrument (Tecan, Durham,
NC, USA). The hybridization protocol and program were as
described for Agilent Two-Colour Microarray-Based Gene
Expression Analysis with TECAN HS Pro hybridization.
Briefly, samples were hybridized to slides for 17 h at 65°C
with high agitation frequency. Slides were scanned at 5-lm
resolution using a GenePix 4200AL scanner (Molecular
Devices, Sunnyvale, CA, USA). Gridding was performed
manually using SpotReader (Niles Scientific Inc., Sacramento,
CA, USA) and the resulting GPR file was analysed using ACUITY 4 software (Molecular Devices). Data was imported and
normalized using a whole slide Lowess normalization routine
provided by Acuity. Analysis and quality control were
assessed with Self-Organizing maps (SOM), Principal Component Analysis (PCA), t-test and volcano plotting of PCA
scores versus log transformation of t-test scores. The top differentially expressed genes were extracted, compiled into lists
and then compared between replicates. Gene Expression
Omnibus microarray data are deposited under GSE54615
accession number and consists of embryonic (GSE54613) and
adult data (GSE546134).

Quantitative real-time PCR
RNA was isolated as described above and treated with TurboDNAse using the TurboDNA-free kit (AM1907; Life Technologies). cDNA synthesis was performed using QuantiTect
Reverse Transcription kit (205311; QIAGEN, Mississauga,
ON, Canada) and quantitative real-time PCR (qRT-PCR)
was performed using QuantiFast SYBR Green PCR kit
(204154; QIAGEN) with theStratagene Mx3000PQPCR system and results were analysed using the MXPROQPCR Software
52

(Agilent Technologies). Quantification was performed using
the 2DDCt method. The primers used are listed in Table SI.
qPCR on genomic DNA from wild-type and transgenic adult
fish was performed using 100 ng of DNA and primers for
EGFP and ryr3 (ryanodine receptor 3), an endogenous gene
with a previously published qPCR assay (Dahlem et al,
2012). Primer efficiencies were estimated from a dilution series of genomic DNA from transgenic fish.

Gene Ontology pathway analysis
Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to analyse enrichments of functional Gene Ontology terms. The gene sets were imported
into DAVID web-based tool, processed using the standard
pipeline and the results were downloaded.

Results
Ubiquitous expression of the human KIT gene with the
D816V mutation
We used the Tol2 kit developed by the Chien Laboratory
which utilizes the Gateway system to generate transgenic expression constructs via recombination-based cloning
(Kwan et al, 2007). The human KIT-D816V construct was
cloned into the middle entry vector and the promoteroncogene-fluorescent tag construct was assembled in a
destination vector with flanking Tol2 sites. The KIT-D816V
coding sequence was combined in-frame with the reporter
enhanced GFP (eGFP) using the viral 2A linker, which allows
for co-translational cleavage of the resulting polypeptide.
Expression of the cassette was driven by the ubiquitous
zebrafish beta actin (actb2) promoter (Fig 1).
After injection of the construct into zebrafish eggs and
growing the positive embryos to adulthood, we identified
three founders (designated A, B and C) whose homozygous
offspring produced close to 100% GFP+ embryos. GFP
expression was ubiquitous in all three transgenic lines. The
B-line was discontinued due to poor survival of the founder
and F1 generation fish. The A and C lines were maintained
up to six generations and raised to adulthood. The C line
was used for all embryo experiments, including WISH,
immunofluorescence studies and microarray due to stronger
expression of GFP in the embryos and availability of larger
clutch sizes. Both A and C lines were used for adult studies,
including kidney dissections and microarray, disease surveillance and histological analysis. There was only one adult fish
from the B-line that was included in the total number.
Expression of KIT-D816V was confirmed by PCR, Sanger
sequencing and Western blot (Fig 1). qPCR on genomic
DNA from adult transgenic fish for EGFP gene copy number
relative to the copy number of an endogenous gene (ryr3)
confirmed a single homozygous insertion of the transgene
(data not shown).
ª 2014 John Wiley & Sons Ltd
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Transgenic adults show signs of disease with evidence of
increased numbers of mast cells in the kidney marrow
A total of 232 Tg(actb2::KIT-D816V::2AeGFP) transgenic zebrafish (heretofore referred to as the KIT-D816V line) were
grown to adulthood and observed by regular daily surveillance for evidence of disease. At the time this manuscript
was prepared, 144 (62%) fish had either died or been sacrificed at a median of 15 months (range 3–30 months).
Twenty-eight of these fish (12% of total) were sacrificed
while seemingly healthy for surveillance purposes. The
remaining 116 (50% of total number of fish; ‘prevalence’)
had either died spontaneously or been sacrificed because of
various signs of disease (Fig 2). The median age of the latter
group (‘age of onset’) was also 15 months (range 3–
30 months). Between founder lines A and C, there was no
statistically significant difference in median age of onset of
disease, (16 [6–26] and 14 [3–30] months respectively,
P = 011) or disease prevalence (528% and 484% respectively, P = 057).
The physical findings in sick fish included raised scales,
distended abdomen, skin lesions and external bleeding
(n = 39); thin and emaciated appearance with or without
additional lesions (n = 29); and gross evidence of visceral
masses (n = 8). Twenty (18%) of the sick fish were dissected
for histological analysis. Of those 20, 12 fish (60%) had an
abnormal histological appearance (Fig 2). Again, there was
no statistically significant difference in the percentage of fish

with abnormal histology between the founder lines (625% in
the A-line vs. 583% in the C-line, P = 1).
The most common finding was kidney marrow expansion,
with distortion of the normal tubular structures and an
increased number of PAS-positive cells, suggesting a myeloid
predominance (Fig 3. Compare E–G with A–C). Tryptase
immunohistochemistry revealed increased numbers of positive cells in the kidney marrow compared to wild-type
(Fig 3, compare H–D), supporting the idea that a proportion
of the cells in the expanded myeloid compartment of the disorganized adult kidney marrow were mast cells. In several of
the sick fish, findings were even more dramatic with complete effacement of normal kidney architecture and tremendous expansion of PAS+/tryptase+ cells that infiltrated into
neighbouring organs, suggesting progression to a mast cell
predominant myeloproliferative neoplasm (Fig 3I–L, Figure
S1).

Microarray analysis of adult kidneys shows an increased
expression of mast cell proteases in KIT-D816V fish
compared to wild-type
To study mechanisms of adult haematopoietic disease phenotypes induced by KIT-D816V, we performed microarray
experiments on pooled kidneys excised from normal wildtype and diseased KIT-D816V adults. The microarrays were
performed on a single pooled sample from each genotype
using two-colour dye-swap design. Genes showing the same

Fig 2. Flow chart of disease manifestations and pathology in adult KIT-D816V transgenic zebrafish demonstrates high prevalence of SM-like phenotype. Cross-sectional representation of macroscopic and microscopic findings in adult transgenic fish revealed a high prevalence of disease. Of
the total number of transgenic fish (n = 232), half demonstrated obvious signs of disease; mostly in the form of distension, emaciation or visceral
masses, as shown in representative images to the right of the boxes. ‘Other’ phenotypes included infections, skin lesions, bleeding from orifices or
lesions, hypopigmentation and sickly appearance. A subset (177%) of the sick fish were sectioned for further analysis and 60% of these sectioned
sick fish showed evidence of disease pathology, in the form of a myeloproliferative disease in the haematopoietic kidney marrow. The numbers
and percentages are shown in grey boxes below each group. The percentage of each group refers to the ratio of that subset within the above
group.
ª 2014 John Wiley & Sons Ltd
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Fig 3. Adult KIT-D816V transgenic zebrafish exhibit a mast cell myeloproliferative phenotype in their kidney marrow. (A–D) In the wild type
adult kidney, the organization of tubuli and glomeruli can be easily distinguished in H&E stained images (A, B); a few cells in the interstitium
(C) are stained with Positive Acid Schiff (PAS+) and no tryptase-positive cells are present in this section (tubular cells take up non-specific stain)
(D). (E–H) A 16-month-old female fish became sick and had a protruding lesion from its urogenital pore. Kidney marrow was expanded and disorganized, with increased numbers of PAS+ cells (E–G). Tryptase immunostaining was positive for a large proportion of cells in the kidney marrow (H). (I–L) A 6-month-old female fish grew a skin lesion on her back. The kidney was disorganized and the regular tubular structures were
effaced (I, J). Increased numbers of PAS+ cells in the kidney marrow can be seen (K) as well as many cells positive for tryptase immunostaining
(L).

direction (up or down) of differential expression in at least
two microarray experiments were included in the final list of
regulated genes. Strikingly, analysis of the differential genes
between wild-type and KIT-D816V adult kidney datasets
revealed 73 up-regulated genes, many of them encoding proteolytic enzymes typically expressed at high levels in mast
cells and 71 down-regulated genes (Table SII). Gene Ontology analysis of the adult data set was also able to detect
enrichment for ‘proteolysis’, ‘metallopeptidase activity’, ‘serine endopeptidase activity’ terms as well as a ‘myofibril
assembly’ term which may be the result of a small muscle tissue contamination (Table I). These genomic findings suggest
greater numbers of mast cells in adult kidneys of KIT-D816V
fish, consistent with and complementing the pathology data
presented in Fig 3.

Embryonic WISH studies reveal no prominent
haematopoietic phenotype
By contrast to the adult phenotype, WISH analysis of
KIT-D816V transgenic embryos at multiple developmental
time points [from 12 h post-fertilization (hpf) to 7 d
post-fertilization (dpf)] did not reveal a prominent change in
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haematopoietic markers. The mast cell specific marker, cpa5,
was not increased at 28 hpf, the earliest time point when it
is most robustly expressed (Dobson et al, 2008); or at later
stages of development (48 and 72 hpf; 5 and 7 dpf). There
was a slight increase in expression levels of the stem cell marker, gata2 at 20 hpf (normal expression at 16, 24 and
28 hpf), and a decrease in expression was observed for the
early pan-myeloid marker spi1b, most prominently at 24 hpf.
No changes in expression were observed for additional myeloid (mpx, lcp1, csf1ra, cebpa) or erythroid markers (hbbe3,
gata1) (Figure S2).

Hyperactive KIT perturbs cell-cycle progression and
increases apoptosis levels in transgenic embryos
Whole mount apoptosis and cell cycle assays were performed
on transgenic embryos as well as on wild type AB control
embryos. Apoptosis levels were examined using active Caspase 3 staining in 28 hpf embryos. Imaging of active Caspase
3 (Fig 4A) followed by intensity threshold-based statistical
analysis of labelled area fractions revealed a small but significant increase in apoptosis levels in KIT-D816V compared to
wild-type embryos (Fig 4B). To investigate the effects of
ª 2014 John Wiley & Sons Ltd
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Table I. Enriched Gene Ontology terms in the biological process and molecular function categories.
Term – biological process

Count

GO:0006508 – proteolysis

20

10 9 106

4

69 9 1011

GO:0030239 – myofibril assembly

P-value

Term – molecular function
GO:0004252 – serine-type endopeptidase activity

Genes
zgc:92511, zgc:92590, cpa4, zgc:112368, zgc:112160, ctrb1, c6ast3, ttnb, c6ast4,
zgc:66382, zgc:112302, zgc:136461, ufm1, zgc:92041, ela2l, try, ela2, cpb1, ela3l, ctrl
myl7, cmlc1, ttnb, tpm4

Count
14

P-value

Genes
3

77 9 10

GO:0015082 – di-, tri-valent inorganic
cationtransmembrane transporter activity
GO:0005509 – calcium ion binding
GO:0005529 – sugar binding

3

28 9 102

9
4

29 9 102
35 9 102

GO:0008237 – metallopeptidase activity
GO:0005388 – calcium-transporting ATPase activity

4
2

74 9 102
77 9 102

KIT-D816V on cell cycle progression leading to mitosis (G2
to M phase transition), we completed phospho-S10 histone
H3 (pH3) labelling at 28 and 48 hpf (Shepard et al, 2004).
Using similar imaging and analysis techniques, a consistent
and significant decrease in pH3 labelling was observed in
transgenic compared to wild type embryos at both 28 and
48 hpf (Fig 4C, D), suggesting a cell-cycle progression defect
in the transgenic embryos in the context of a constitutively
active KIT background.

Pattern of differentially expressed genes in KIT-D816V
embryos reflects an altered cell cycle phenotype
To gain insight into potential molecular mechanisms of cellcycle effects and to identify KIT-D816V-regulated genes, we
conducted microarray expression profiling of 28 hpf embryos
of wild-type and KIT-D816V genotypes. This time point was
chosen to correspond with the timing of mast cell development, because 28 hpf is the earliest time point when cpa5positive mast cells are easily and robustly detectable (Dobson
et al, 2008). Microarray experiments were performed on
28 hpf embryos four times using two-colour channel swap
microarray design, with evaluation as above for gene expression differences in adult transgenic fish. There were 23 upregulated and 47 down-regulated genes (Table SIII). The
overlap of the embryonic dataset with the set of adult regulated genes was only seven genes (epcam, rrs1, dnmt1, ube2c,
pdf, zgc:195170, si:dkey-23c22.6).We also studied pathway and
Gene Ontology term enrichment for this dataset, but did not
identify significant groups of genes, probably due to the small
number of regulated genes. We verified 11 genes (cyp1a, rrs1,
srsf5a, ccl-c25v, rrm2b, ndrg4, chtf18, rad23b, dnmt1, mt2, epcam) with identifiable functions by qPCR, and seven of these
genes (Fig 5A) could be consistently confirmed. We further
performed WISH for the up-regulated genes: rrm2b, chtf18
and rad23b as well as for the down-regulated genes: dnmt1,
ª 2014 John Wiley & Sons Ltd
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zgc:92590, zgc:92511, zgc:112368, zgc:112160, ctrb1, zgc:66382,
zgc:112302, zgc:136461, zgc:92041, ela2l, ela2, try, ela3l, ctrl
atp2a1l, slc39a13, atp2a2a
pvalb4, myl7, pvalb3, cmlc1, actn3a, mylz3, mylz2, tnnc, stnnc
zgc:153499, si:ch211-226h8.4, si:ch211-154a22.8,
si:dkeyp-46h3.2, si:ch211-226h8.11, zgc:172053
cpa4, c6ast3, c6ast4, cpb1
atp2a1l, atp2a2a

mt2 and epcam. Consistent increases of WISH signal in KITD816V embryos were observed for rrm2b, chtf18 and rad23b
(Fig 5B). Interestingly, Rrm2b is required for DNA repair in
quiescent cells and mitochondrial DNA maintenance (Pontarin et al, 2012). Two other up-regulated genes, rad23b and
chtf18, are also involved in DNA repair, where Rad23b regulates nucleotide excision repair (Ng et al, 2003), while Chtf18
is required for DNA polymerase epsilon loading onto DNA
(Ogi et al, 2010). Thus, changes in expression of these genes
may be related to the cell cycle phenotypes in KIT-D816V
embryos we observed (Fig 4). WISH with probes for the
down-regulated genes also showed expression differences for
mt2, dnmt, and epcam genes (Fig 5B). Metallothionein 2
(Mt2) is involved in protection against heavy metals, oxidative stress and promoting cell survival (Swindell, 2011). It is
expressed in wild-type embryos at 28 hpf in cells covering the
yolk, as well as some unknown cells of probable haematopoietic origin, as this is one of the known expression domains in
the mouse as reviewed in (Swindell, 2011). Expression of mt2
was strongly decreased in KIT-D816V transgenic zebrafish
embryos (Fig 5B).

Functional follow-up of dnmt1 and epcam downregulation in 28 hpf KIT-D816V transgenic embryos
Dnmt1 (DNA methyltransferase I) is the principal enzyme
responsible for maintaining CpG island methylation and
along with other DNA methyltransferases, has been implicated in haematopoietic and leukaemic stem cell renewal
(Trowbridge et al, 2009, 2012). Interestingly, dnmt1 was consistently down-regulated in both embryonic and adult microarray datasets and its regulation was confirmed by qPCR and
by WISH in embryos (Fig 5). By contrast, comparable levels
of DNA methylation were observed in wild-type and KITD816V embryos analysed both by restriction digest and antibody-based slot-blot techniques (data not shown). Thus, the
55

T. B. Balci et al

(A)

(B)

(C)

(D)

decrease in dnmt1 expression in KIT-D816V embryos did
not result in significant changes in global methylation. However, we cannot exclude other effects of dnmt1 decrease on
gene expression.
Down-regulation of the epcam gene in KIT-D816V fish
was observed in both embryonic and adult microarray
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Fig 4. Cell cycle and apoptosis assays suggest
an increase in apoptosis and a putative block
in G2/M transition in KIT-D816V transgenic
embryos. (A) Active Caspase 3 labelling of
wild-type and KIT-D816V transgenic embryos
at 28 hpf. Staining was completed on a total of
50 embryos for each genotype in three independent experiments and representative images
are shown. Embryos are displayed in side profile, anterior to the left. (B) Statistical analysis
of the labelled area fractions relative to wildtype shows an increase in the active Caspase 3
labelling in KIT-D816V transgenic embryos
(***P-value <0001). (C) G2/M cells were
labelled by anti-phospho-histone H3 (pH3)
antibody staining in wild-type and KIT-D816V
transgenic embryos at 28 and 48 hpf. Representative images show magnified views of the
tail region used for quantification. Embryos are
displayed in side profile, anterior to the left.
(D) Quantification of anti-phospho-histone H3
staining in wild-type and KIT-D816V embryos
at 28 and 48 hpf shows a decrease in mean relative pH3-labelled area fractions at both stages.
The analysis was performed at 28 hpf on 23
wild-type and 26 KIT-D816V embryos (**t-test
P-value <001) and at 48 hpf on 35 wild-type
and 49 KIT-D816V embryos (***t-test P-value
<0001), in two independent experiments at
both stages. (hpf = hours post-fertilization).

datasets, suggesting that this gene is highly responsive to
activity of KIT-D816V in zebrafish. We also were able to
confirm its lower expression level by both qPCR and WISH
in embryos (Fig 5). Expression of epcam was reduced in
most of its expression domains such as the epidermis, gastrointestinal tract, lateral line system and olfactory region
ª 2014 John Wiley & Sons Ltd
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(A)

(B)

Figure 5. Confirmation of selected differentially expressed genes between 28 hpf wild-type and KIT-D816V embryos identified by microarraybased gene expression profiling. (A) Changes of expression (log2 fold changes) of ccl-c25v, rrm2b, chtf18, rad23b, dnmt1, mt2 and epcam genes
identified by microarray and quantitative PCR (qPCR). The values for microarray experiments are from 2 to 4 hybridizations and for qPCR are
from three independent experiments. Mean and standard deviations are shown in the graph. (B) Whole mount in situ hybridisation (WISH)
assays for rrm2b, chtf18, rad23b (up-regulated), dnmt1, mt2 and epcam (down-regulated) genes in wild type (wt) and KIT-D816V zebrafish
embryos were performed on 30 embryos in two independent experiments and the representative images are shown.

(Fig 5B). Although epcam is not known to be directly
involved in mast cell biology and function, it has several
roles in regulating cell adhesion, functions as a transcription
factor and promotes cell proliferation and tumour growth
(Schnell et al, 2013). In zebrafish, knock-down of epcam
results in defects in the lateral line primordium migration
and reduced deposition of neuromast groups of sensory
cells (Villablanca et al, 2006). We used enumeration of
ª 2014 John Wiley & Sons Ltd
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neuromasts to assess if expression of KIT-D816V has a biological effect in this context. There was indeed a significant
reduction in the number of visually discernible neuromasts
in KIT-D816V embryos and their sizes were typically smaller (Fig 6). While this finding requires additional evaluation
in the context of KIT-D816V function, it provides an easy
and rapid visual read-out of KIT-D816V effects in our
transgenic model.
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(A)
(B)

Fig 6. Neuromast quantification in 48 hpf wild-type and KIT-D816V embryos. (A) Representative examples of 48 hpf wild-type and KIT-D816V
embryos stained with nitro-blue tetrazolium and 5-bromo-4-chloro-30 -indolyphosphate (NBT-BCIP) to detect endogenous alkaline phosphatase
(AP) are shown. Neuromasts are marked with the black triangles. (B) Neuromasts were manually counted on a single side in 24 wild-type and 31
KIT-D816V embryos in two independent experiments, and the data from both experiments was combined demonstrating a significant decrease in
the transgenic embryos (***indicates statistical significance <0001, which in this case was P = 498*10e-6 by non-parametric Mann–Whitney
test). Mean and standard errors are shown in the graph.

Discussion
Here we describe the first zebrafish model of human SM,
employing the human KIT-D816V mutant gene under a ubiquitous zebrafish promoter. Use of the human gene construct
predicts greater fidelity and reliability in the translation of
results observed for collaborating molecular pathways and
responses to therapy. Confirmation of germline expression and
penetrance of disease phenotype in our adult transgenic fish
dispels previously raised concerns regarding embryonic lethality of animal models with germline expression of human
KIT-D816V and more subtle manifestations of disease due to
limited conservation of cross-species intracellular signalling
(Gerbaulet et al, 2011). The incidence of disease in our transgenic zebrafish expressing human KIT-D816V is significantly
greater than in the transgenic mice overexpressing the same
human mutant gene observed in an earlier study (50% vs.
30%) albeit with similar disease latency (Zappulla et al, 2005).
Of the diseased fish that were dissected, a significant proportion (60%) showed abnormal histology in the form of myeloproliferation and mast cell expansion. Because it was
technically not feasible to dissect all fish with signs of disease
(n = 116), we can only postulate that this percentage reflects
the actual disease prevalence in our line. The absence of overt
disease by histology in 40% of fish may be due to a number of
reasons. In the case of two of these eight fish, the tissues were
too disintegrated to effectively analyse the number of myeloid
cells in the kidney marrow, as the presentation of these fish was
‘sudden death’. We have classified these fish under ‘normal histology’ due to lack of an overt disease that could be appreciated
in the sections. In the remainder of fish, we can speculate that
the difference in phenotype is in keeping with the extensive
clinical variability of human SM in adults, ranging from indolent to a fulminant myeloproliferative disease.
Despite the phenotypic variability, these transgenic fish
represent the first animal model with clinical features in
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keeping with aggressive SM or mast cell leukaemia (MCL),
with accumulation of mast cells and a myeloproliferative
neoplasm (MPN)-like phenotype specifically in the kidney
marrow, features not seen in transgenic mice overexpressing
either human KIT-D816V or the more potent murine KitD814V (Gerbaulet et al, 2011). Mice expressing Kit-D814V
also exhibited some unusual disease characteristics not
entirely in keeping with the human disease, such as an
embryonic lethal hyperproliferative erythroid dysregulation
in non-inducible transgenic animals, concurrent prominent
B-precursor acute leukaemia, and intestinal inflammation
(Gerbaulet et al, 2011). By contrast, expression of human
KIT-D816V early in development using the b-actin promoter
did not result in these manifestations in our zebrafish
model. In fact, as was observed in transgenic mouse embryos
expressing human KIT-D816V (Zappulla et al, 2005), our
transgenic zebrafish embryos did not demonstrate any signs
of mast cell pathology, as evidenced by no decrease in overall
survival and normal embryonic haematopoiesis. The latency
of a mastocytosis phenotype in transgenic embryos may
reflect the potency of the oncogenic signal or may be related
to the choice of promoter. Currently, no exclusive mast cellexpressing promoters are available in the zebrafish. We have
been developing a cpa5-based knock-in of a fluorescent protein gene or an exogenous transcription factor gene such as
Gal4 using clustered regularly interspaced short palindromic
repeats (CRISPRs) (S.V. Prykhozhij and J.N. Berman, unpublished data). The b-actin promoter was chosen on account of
its track record in generating haematopoietic malignancies
and in particular, its efficacy in promoting pre-B ALL in a
model of ETV6-RUNX1 -driven leukaemia, when the lymphoid-specific rag2 promoter was unsuccessful (Sabaawy
et al, 2006). This study suggested that the use of ubiquitous
promoters active earlier in zebrafish blood development may
prove more robust at driving leukaemic transformation.
Despite an early disease manifestation in this study, incidence
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was very low at 3% of fish, which is in contrast to the high
penetrance but late onset of KIT-D816V expressing fish seen
in our study. These data indicate the importance of careful
interpretation of manifestations when using a ubiquitous
promoter and raises the question of whether a mast cell-specific promoter may result in an earlier, more robust disease
phenotype.
A unique opportunity afforded by the zebrafish model is
the ability to compare embryonic and adult phenotypes of a
transgenic system to unravel the putative transforming events
in the course of a disease. The high genomic conservation
and local synteny between the human and zebrafish genomes
make genome-scale analysis by microarray a powerful method
for translational research and medical discovery. However,
the choice of promoter in our transgenic model may have
similarly had an impact on the relatively few genes differentially expressed in zebrafish embryos overexpressing KITD816V. The ubiquitous expression may have led to incompatible signalling adapters and downstream molecules, as well as
potential masking of significant expression changes in specific
tissues. While a specific mast cell or haematopoietic phenotype was not observed in KIT-D816V embryos either by
WISH or microarray, down-regulation of epcam and
decreased numbers of neuromasts provides a consistent surrogate assay that could be employed in an embryonic chemical screen to identify compounds that restore normal epcam/
neuromast expression. Such a compound, in turn, may have
the potential to impact the biological effects of KIT overexpression found in human mast cell diseases harbouring the
D816V mutation. This is particularly relevant, given the
strong aggressive mastocytosis phenotype observed in adult
KIT-D816V transgenic fish, which also exhibit down-regulation of epcam. The most upregulated genes in adult affected
kidneys were endopeptidases, mirroring microarray results
from the bone marrows of human mastocytosis patients
(D’ambrosio et al, 2003), although we did not similarly
observe increased expression levels of oncogenes, cell cycle
genes or haematopoietic transcription factors, such as gata2.
KIT-D816V transgenic embryos also demonstrated evidence of a cell-cycle defect, which ultimately would need to
be overcome later in development to result in the proliferative mast cell disorder observed in adult fish. Interestingly,
we have described another transgenic zebrafish line overexpressing the human NUP98-HOXA9 transgene found in high
risk acute myeloid leukaemia that similarly develops an MPN
phenotype in the adult kidney marrow (Forrester et al,
2011). In contrast to the KIT-D816V line, NUP98-HOXA9
embryos demonstrated no increase in BrdU or pH3 labelling
under steady-state conditions, but in fact have significantly
elevated dnmt1 expression (Deveau et al, 2012). While the
functional significance of decreased dnmt1 expression
remains to be elucidated in the KIT-D816V model, these
contrasting findings suggest different mechanisms and roles
of epigenetic regulation in these two transgenic zebrafish
models resulting in an adult MPN phenotype.
ª 2014 John Wiley & Sons Ltd
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Given its similarity to chronic myeloid leukaemia regarding
a constitutively active tyrosine kinase as an underlying molecular pathology, SM with a KIT-D816V mutation has been the
subject of many clinical trials with known and novel tyrosine
kinase inhibitors, as reviewed in Ustun et al (2011) and
Pardanani (2012), however it remains a disease without a
definitive cure. With the overall results of these targeted therapies being far from satisfactory, there is a clear need for additional models to better elucidate disease pathogenesis and
enable high-throughput in vivo drug testing. The time and
expense required for many of the current mouse models of
myeloproliferative diseases and leukaemia have hampered the
application of the mouse model system. These challenges have
also encouraged the emergence of the zebrafish, largely owing
to the distinct advantages afforded by the large numbers of
rapidly-developing externally-fertilized embryos that can be
easily manipulated and subjected to large-scale chemical modifier screens. While there are limitations with regards to the
expression data described above that can be improved upon
in future transgenic models by incorporating mast cell-specific
promoters and other genetic enhancers, the transgenic zebrafish model presented here recapitulates features of aggressive
human SM in the adult kidney marrow and provides embryonic surrogate markers that could be utilized in drug testing.
Importantly, it represents the first zebrafish model of a human
mast cell disease and hearkens at the potential of this versatile
vertebrate system to provide new insights on the pathogenesis
and putative novel therapies for SM and other MPNs.
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